{"id":"W4411333669","doi":"10.1002/hon.70093_136","title":"136 | MINIMAL RESIDUAL DISEASE WITH BENDAMUSTINE‐RITUXIMAB WITH OR WITHOUT ACALABRUTINIB IN PATIENTS WITH PREVIOUSLY UNTREATED MANTLE CELL LYMPHOMA: RESULTS FROM THE ECHO TRIAL","year":2025,"lang":"en","type":"article","venue":"Hematological Oncology","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"ca_institutions":"University of British Columbia","funders":"AstraZeneca","keywords":"Bendamustine; Mantle cell lymphoma; Rituximab; Medicine; Minimal residual disease; Oncology; Internal medicine; Lymphoma; Cancer research; Bone marrow","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005017688,0.0005214405,0.001501919,0.0001654273,0.0001785225,0.00004667269,0.0004803634,0.0004553954,0.0001836958],"category_scores_gemma":[0.001222804,0.0002254754,0.00007889183,0.0009466369,0.0009685422,0.00008617536,0.0002778862,0.000611754,0.00005824541],"about_ca_system_candidate":true,"about_ca_system_consensus":true,"about_ca_system_score_codex":0.003906777,"about_ca_system_score_gemma":0.01371629,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0007696759,"about_ca_topic_score_gemma":0.001666257,"domain_scores_codex":[0.9954423,0.0005743139,0.0009054392,0.001180918,0.0008489643,0.001048084],"domain_scores_gemma":[0.9954226,0.002555331,0.0003185095,0.0009724921,0.0002981104,0.0004329596],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.8539593,0.007595157,0.1291795,0.0001729121,0.0002248622,0.004236125,0.0004369744,0.00001317277,0.000004673715,0.0001030936,0.002756833,0.001317425],"study_design_scores_gemma":[0.8970245,0.01911424,0.0766891,0.0009087987,0.0007572489,0.0001819233,0.000569405,0.0007908097,0.0002368541,0.00004812493,0.003233174,0.000445861],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.987845,0.0001473759,0.00002439889,0.002270338,0.00007651679,0.003923882,0.0001249348,0.0001357896,0.005451744],"genre_scores_gemma":[0.9947765,0.0000319855,0.00179172,0.0009255315,0.0001194636,0.0003663417,0.000373175,0.00004725606,0.001567975],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.05249041,"threshold_uncertainty_score":0.999917,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.02236552243145124,"score_gpt":0.3106704017626135,"score_spread":0.2883048793311622,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}